# Penicillin derivatives, a process for their preparation and compositions containing them.

## Abstract
A compound of formula I or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof

## Claims
A. CLAIMS 1. A compound of formula 1 or a pharmaceutically acceptable salt or an in vivo hydrolysable ester thereof EMI42.1 wherein R represents optionally substituted aryl or heterocyclyl and R1 represents hydrogen, an alkyl, alkenyl, cycloalkyl or cycloalkenyl group, an optionally substituted phenyl, a cyclopropyl alkyl group, a hydroxy group optionally substituted by alkyl, alkenyl, cycloalkyl, phenyl or benzyl, an optionally substituted mercapto group, an alkylsulphenyl group, a free or substituted amino group, an optionally substituted piperazino or phenyl alkylamino group, an acylamino group or an alkyl, aralkyl or arylsulphonyl amino group. 2. A compound as claimed in claim 1 wherein the group R is phenyl, 4 hydroxyphenyl, 3,4 dihydroxy phenyl, 3,4 diacetoxy phenyl, 2 or 3 thienyl, 2 or 3 furyl, 2 ,3 , or 4 chlorophenyl, or 2 , 3 , or 4 fluorophenyl. 3. A compound as claimed in either claim 1 or claim wherein R1 is a substituted amino group. 4. A compound as claimed in any of claims 1 to 3 wherein R1 represents an amino group substituted by an optionally substituted phenyl group. 5. A compound as claimed in claim 1 selected from 6,ss 2 3 2 4 aminosulfonylphenylamino 4 hydroxypyrimidin 5 yl ureido 2 phenylacetamidol 6,5 methoxypenicillanic acid or 6,ss 2 3 4 hydroxy 2 phenylamino pyrimidin 5 yl ureido 2 phenylacetamido 6a methoxy penicillanic acid or 6,ss 2 3 2 4 aminosulphonylphenylamino 4 hydroxypyrimidin 5 yl ureido 2 4 hydroxyphenyl acetamido 6,a methoxypenicillanic acid or 6,k 2 3 2 4 aminosulphonylphenylamino 4 hydroxy pyrimidin 5 yl ureido 2 thien 2 ylacetamido 6,a methoxypenicillanic acid or 6,ss 12 3 2 4 aminosulphonylphenylamino 4 hydroxypyrimidin 5 yl ureido 2 furan 2 yl acetamido 6,a methoxy penicillanic acid or 6,ss 2 3 2 4 aminosulfonylphenylamino 4hydroxypyrimidin 5 yl ureido 2 2 fluorophenyl acetamido 6,a methoxypenicillanic acid or 6,8 2 3 2 4 aminosulphonylphenylamino 4 hydroxy pyrimidin 5 yl ureido 2 4 fluorophenyl acetamido 6, methoxypenicillanic acid or 6,ss 2 3 2 4 aminosulphonylphenylamino 4 hydroxypyrimidin 5 yl ureido 2 3,4 diacetoxyphenyl acetamido 6,a methoxypenicillanic acid or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof. 6. A process for the preparation of a compound as claimed in claim 1 which process comprises A reacting a compound of formula II EMI44.1 wherein the amino group is optionally substituted with a group which permits acylation to take place, R is as defined with respect to formula I and any reactive substituents may be protected, and Rx is hydrogen or a carboxyl blocking group, with an N acylating derivative of an acid of formula III EMI45.1 III wherein R1 is an defined with respect to formula f above, and any reactive groups may be protected B reacting a compound of formula IV as described hereinbefore with an N acylating derivative of an acid of formula VI EMI45.2 wherein R and R1 are as defined with respect to formula I and any reactive groups therein may be protected C by reacting a compound of formula VII EMI45.3 wherein R, R1 and RX are as defined above and R2 is C1 6 alkyl, aryl or benzyl either i with methanol in the presence of a metal ion, such as mercury, lead, silver, cadmium, thallium, or bismuth or ii with chlorine or bromine at 250C to 8O0C and subsequently decomposing the resultant halosulphonium halide with methanol and a base orD by a treating a compound of formula IX EMI46.1 wherein Rx is a carboxyl blocking group, and R is an acyl group, in particular an acyl group derived from side chain of a natural penicillin, such as benzyl penicillin or phenoxymethyl penicillin with an agent forming an imino halide b treating the imono halide with a compound to introduce a group QRf of the imino carbon atom, whereinQ is oxygen, sulphur or nitrogen and Rf is an alkyl group of from 5 to 14 carbon atoms, to form an iminoether, iminothioether, or amide when Q is O, S, orN respectively

## Description
EMI1.1 wherein R represents optionally substituted aryl or heterocyclyl and R1 represents hydrogen, an alkyl, alkenyl, cycloalkyl or cycloalkenyl group, an optionally substituted phenyl, a cyclopropyl alkyl group, a hydroxy group optionally substituted by alkyl, alkenyl, cycloalkyl, phenyl or benzyl, an optionally substituted mercapto group, an alkylsulphenyl group, a free or substituted amino group, an optionally substituted piperazino or phenyl alkylamino group, an acylamino group or an alkyl, aralkyl or arylsulphonyl amino group. The term heterocyclyl includes single or fused rings comprising up t6 four hetero atoms in the ring selected from oxygen, nitrogen and sulphur and optionally substituted with up to three halogen, C1 6 alkyl, C16 alkoxy, halo C1 6 alkyl, hydroxy, amino, carhoxy, C16 alkoxycarbonyl, C1 6 alkoxycarbonyl C1 6 alkyl, aryl or oxo groups. Suitably the heterocyclic ring comprises from 4 to 7 ring atoms, preferably 5 to 6 atoms. When used herein the term aryl includes phenyl and naphthyl optionally substituted with up to five, preferably up to three, groups selected from halogen, C1 6 alkyl, phenyl, C16 alkoxy, halo C1,6 alkyl, hydroxy, amino, nitro, carboxy, C16 alkoxycarbonyl, C1 6 alkoxycarbonyl C1,6 alkyl C1 6 alkylcarbonyloxy, or C16 alkylcarbonyl groups. Examples of suitable pharmaceutically acceptable in vivo hydrolysable ester groups include those which break down readily in the human body to leave the parent acid or its salts, for example acyloxyalkyl groups, such as acetoxymethyl, pivaloyloxymethyl, a acetoxyethyl and a pivaloyloxyethyl groups alkoxycarbonyloxyalkyl groups, such as ethoxycarbonyloxymethyl and a ethoxycarbonyloxyethyl dialkylaminoalkyl groups, such as dimethylaminomethyl, dimethylaminoethyl, diethylaminomethyl or diethylaminoethyl and lactone groups such as phthalidyl or dimethoxyphthalidyl. Suitable pharmaceutically acceptable salts of the compounds of formula I include metal salts, eg aluminium, alkali metal salts such as sodium or potassium, alkaline earth metal salts such as calcium or magnesium and ammonium or substituted ammonium salts, for example those with lower alkylamines such as triethylamine, hydroxy lower alkylamines such as 2 hydroxyethylamine, bis 2 hydroxyethyl amine or tri 2 hydroxyethyl amine, cycloalkylamines such as bicyclohexylamine, or with procaine, dibenzylpiperidine, N benzyl B phenethylamine, dehydroabietylamine, N,N bisdehydroabietylamine, ethylenediamine, or bases of the pyridine type such as pyridine, collidine or quinoline. The carbon atom marked in formula I is asymmetric and the compound may be derived from the side chain having a D, L or DL configuration at that position. All forms of compound I are included in this invention. Suitably, the carbon atom marked is derived from the D configuration and is conveniently referred to as the D penicillin derivative. Compounds within formula I may occur in two or more tautomeric forms, all such forms are within the scope of the present invention. In formula I , the group R is preferably 2 or 3 thienyl, 2 or 3 furyl, 2 aminothiazolyl, cyclohexyl, cyclohexen l yl, cyclohexa 1,4 dien l yl, or monoor di substituted phenyl wherein the substituents are selected from halogen, especially fluorine and chlorine, hydroxy, acetoxy and methoxy. In particular R may represent phenyl, 4 hydroxyphenyl, 3,4 dihydroxyphenyl, 3,4 diacetoxyphenyl, or 2 or 3 thienyl,2 or 3 fufljl, or 4 chlorophenyl, or 2 , 3 , or 4 fluorophenyl. Suitably R1 represents a substituted amino group. More suitably R1 represents an amino group substituted by an optionally substituted phenyl group.The substituent for the phenyl group is preferably in the para position and is selected from amino, alkylamino, C16 alkyl, hydroxy, alkoxy and aminosulphonyl. Preferred groups R1 are aminosulphonylphenylamino, and phenylamino Specific compounds within this invention include the following 6, D 2 3 2 4 aminosulphonylphenylamino 4 hydroxypyrimidin 5 yl ureido 2 phenylacetamido 6,5 methoxypenicillanic acid and 6ss D 2 3 4 hydroxy 2 phenylamino pyrimidin 5 yl ureido 2 phenylacetamido 6a methoxy penicillanic acid and 6, D 2 3 2 4 aminosulphonylphenylamino 4 hydroxypyrimidin 5 yl ureido 2 4 hydroxyphenyl acetam ido 6, methoxypenicillanic acid and 6ss D 2 3 2 4 aminosulfonylphenylamino 4hydroxy pyridin 5 yl ureido 2 thien 2 yl acetamido 6, alpha methoxypenicillanic acid and 6, L 2 3 2 4 aminosulphonylphenylamino 4 hydroxy pyrimidin 5 yl tnreido 2 thien 2 yl acetamidor 6a methoxypenicillanic acid and 6,ss D,L 2 3 2 4 aminosulfonylphenylamino 4 hydroxypyrimidin 5 yl ureido 2 furan 2 yl acetamido 6, alpha methoxy penicillanic acid and 6,ss D,L 2 3 2 4 aminosulfonylphenylamino 4 hydroxypyrimidin 5 yl ureido 2 2 fluorophenyl acetamido 6, alpha methoxypenicillanic acid and 6,ss D,L 2 3 2 4 aminosulfonylphenylamino 4 hydroxypyrimidin 5 yl ureido 2 2 fluorophenyl acetamido 6, alpha methoxypenicillanic acid and 6,ss D,L 2 3 2 4 aminosulfonylphenylamino 4 hydroxypyrimidin 5 yl ureido 2 3,4 diacetoxyphenyl acetamido 6, methoxypenicillanic acid. The compounds of formula I may be prepared by reacting a compound of formula II EMI5.1 wherein the amino group is optionally substituted with a group which permits acylation to take place, R is as defined with respect to formula ÃŒ and any reactive substituents may be protected, and Rx is hydrogen or a carboxyl blocking group, with an N acylating derivative of an acid of formula III EMI5.2 wherein R1 is as defined with respect to formula I above, and any reactive groups may be protected and thereafter, if necessary, carrying out one or more of the following steps i removing any carboxyl blocking group RX ii removing any protecting groups on the side chain group iii converting the product into a salt or in vivo hydrolysable ester thereof. Suitable groups which permit acylation to take place and which are optionally present on the amino group of the starting material of the formula II include N silyl, N stannyl and N phosphorus groups, for example trialkylsilyl groups such as trimethylsilyl, trialkyltin groups such as tri n butyltin, groups of formula P.RaRb wherein Ra is an alkyl, haloalkyl, aryl, aralkyl, alkoxy, haloalkyl, aryl, aralkyl, alkoxy, haloalkoxy, aryloxy, aralkyloxy or dialkylamino group, Rb is the same as Ra or is halogen or Ra and Rb together form a ring suitable such phosphorus groups being P OC2H5 2, P C2H5 2,EMI6.1 Suitable carboxyl blocking derivatives for the group C02RX in formula II include salts and ester derivatives of the carboxylic acid. The derivative is preferably one which may readily be cleaved at a later stage of the reaction. Suitable salts include metal salts, such as those with sodium, potassium and lithium, and tertiary amine salts, such as those with trilower alkylamines, N ethylpiperidine, 2,6 lutidine, pyridine, N methylpyrrolidine, dimethylpiperazine. A preferred salt is with triethylamine. Suitable ester forming carboxyl blocking groups are those which may be removed under conventional conditions. Such groups for Rx include benzyl, p methoxybenzyl, 2,4, 6 trimethylbenzyl, 3,5 di t butyl 4 hydroxy benzyl, benzoylmethyl, p nitrobenzyl, 4 pyridylmethyl, 2,2,2 trichloroethyl, 2,2 ,2 tribromoethyl, diphenylmethyl, triphenylmethyl, adamantyl, 2 benzyloxyphenyl, 4 methylthiophenyl, tetrahydrofur 2 yl, tetrahydropyran 2 yl, pentachlorophenyl, p toluenesulphonylethyl, methoxymethyl, a silyl, stannyl or phosphorus containing group, such as described above, an oxime radical of formula N CHRo where RO is aryl or heterocyclic, or an in vivo hydrolysable ester radical such as defined above. The carboxyl group may be regenerated from any of the above esters by usual methods appropriate to the particular Rx group, for example, acid and base catalysed hydrolysis, or by enzymically catalysed hydrolysis, or by hydrogenation. A reactive N acylating derivative of the acid III is employed in the above process. The choice of reactive derivative will of course be influenced by the chemical nature of the substituents of the acid. Suitable N acylating derivatives include an acid halide, preferably the acid chloride or bromide.Acylation with an acid halide may be affected in the presence of an acid binding agent for example, tertiary amine such as triethylamine or dimethylaniline , an inorganic base such as calcium carbonate or sodium bicarbonate or an oxirane, which binds hydrogen halide liberated in the acylation reaction. The oxirane is preferably a C1 6 1,2ralkylene oxide such as ethylene oxide or propylene oxide. The acylation reaction using an acid halide may be carried out at a temperature in the range 5O0C to 5O0C, preferably 2O0C to 200C, in aqueous or non aqueous media such as aqueous acetone, aqueous tetrahydrofuran, ethyl, acetate dimethylacetamide, dimethylformamide, acetonitrile, dichloromethane, l,2 dichloroethane, or mixtures thereof.Alternatively, the reaction may be carried out in an unstable emulsion of water immiscible solvent, especially an aliphatic ester or ketone, such as methyl isobutyl ketone or butyl acetate. The intermediate compound of formula II may be prepared by reacting a compound of formula IV EMI8.1 wherein the amino group is optionally substituted with a group which permits acylation to take place and Rx is as defined with respect to formula II above, with anN acylating derivative of an acid of formula V EMI8.2 wherein R is as defined with respect to formula I and any reactive groups therein may be protected and RZ is an amino protecting group and thereafter removing protection group RZ. Suitable N acylating derivatives, carboxyl protecting groups and reaction conditions include those described hereinbefore. Suitable amino protecting groups RZ are those well known in the art which may be removed under conventional conditions without disruption of the remainder of the molecule. The starting material of formula IV is disclosed in British Patent No. 1 339 007. The compound of formula I may also be prepared by reacting a compound of formula IV as described hereinbefore with an N acylating derivative of an acid of formula VI EMI9.1 wherein R and R1 are as defined with respect to formula I and any reactive groups therein may be protected and thereafter, if necessary, carrying out one or more of the following steps i removing any carboxyl blocking group RX ii removing any protecting groups on the side chain group iii converting the product into a salt or in vivo hydrolysable ester thereof. Compounds of formula I may also be prepared by reacting a compound of formula VII EMI9.2 wherein R, R1 and Rx are as defined above and R2 is C16 alkyl, aryl or benzyl A with methanol in the presence of a metal ion, such as mercury, lead, silver, cadmium, thallium, or bismuth or B with chlorine or bromine at 250C to 800C and subsequently decomposing the resultant halosulphonium halide with methanol and a base. The intermediate compound of formula II may also be prepared by reacting a compound of formula VIII EMI10.1 wherein R, R2 and Rx are as defined above and RY is hydrogen or a group RZ as defined above A with methanol in the presence of a metal ion, such as mercury, lead, silver, cadmium, thallium or bismuth or B with chlorine or bromine at 250C to 800C and subsequently decomposing the resultant halosulphonium halide with methanol and a base. The reaction with methanol in the presence of a metal ion may generally be carried out at a temperature of from 500C to 250C, but is conveniently carried out between 5 C and 250C. Any suitable solvent may be employed. It is generally convenient however to use methanol as the solvent. Preferably R2 represents methyl. Compounds of formula I may also be prepared by a treating a compound of formula IX EMI11.1 wherein Rx is a carboxyl blocking group, and R3 is an acyl group, in particular an acyl group derived from side chain of a natural penicillin, such as benzyl penicillin or phenoxymethyl penicillin with an agent forming an imino halide b treating the imino halide with a compound to introduce a group QRf on the imino carbon atom, wherein 9 is oxygen, sulphur or nitrogen and Rf is an alkyl group of from 5 to 14 carbon atoms, to form an iminoether, iminothioether, or amidine when Q is 0, S, or N respectively c reacting with an N acylating derivative of an acid of formula VI d treating with water and e optionally removing the carboxyl blocking group Rx. A suitable agent for preparing an amino halide is an acid halide in the presence of an acid binding agent such as a tertiary amine, eg. pyridine, triethylamine, or N,N dimethylaniline. Examples of suitable acid halides are phosphorus pentachloride, phosgene, phosphorous pentabromide, phosphorus oxychloride, oxalyl chloride and p toluene sulphonic acid chloride. Phosphorus pentachloride and phosphorus oxychloride are preferred. The reaction may be conducted under cooling, preferably at temperatures from OOC to 300C when phosphorus pentachloride is employed. The amount of the tertiary amine is preferably 3 5 mols per mol of phosphorus pentachloride. It is also preferable to use the phosphorus halide in an amount slightly in excess of that of the starting material. The resulting imino compounds are then treated to introduce a QRf group onto the imino carbon atom.This is preferably effected by reacting the imino halide with a corresponding alcohol. Examples of suitable alcohols for reaction with the imino halide are aliphatic alcohols containing from 1 to 12 carbon atoms, preferably 1 to 5 carbon atoms, such as methanol, ethanol, propanol, isopropyl alcohol, amyl alcohol and butyl alcohol, and aralkyl alcohols such as benzyl alcohol and 2 phenylethanol. The reaction of the alcohol with the imino halide is preferably effected in the presence of an acid binding agent, such as a tetiary amine, preferably pyridine, and the reaction is usually carried out without isolating the imino halide from the reaction mixture. Finally, the product is treated with water. The water treatment may be conducted together with the isolation of the desired material. That is the reaction mixture may be added to water or a saturated aqueous solution of sodium chloride and then the aqueous layer formed is separated from the organic solvent layer. The antibiotic compounds according to the invention may be formulated for administration in any convenient way for use in human or veterinary medicine, by analogy with other antibiotics, and the invention therefore includes within its scope a pharmaceutical composition comprising a compound of formula I above together with a pharmaceutical carrier or excipient. The composition may be formulated for administration by any route, such as oral topical or parenteral. The compositions may be in the form of tablets, capsules, powders, granules, lozenges, creams or liquid preparations, such as oral or sterile parenteral solutions or suspensions. Tablets and capsules for administration may be in unit dose presentation form, and may contain conventional excipients such as binding agents, for example syrup, acacia, gelatin, sorbitol, tragacanth, or polyvinylpyrollidone fillers, for example lactose, sugar, maize starch, calcium phosphate, sorbitol or glycine, tabletting lubricants, for example magnesium stearate, talc, polyethylene glycol or silica disintegrants, for example potato starch or acceptable wetting agents such as sodium lauryl sulphate. The tablets may be coated according to methods well known in normal pharmaceutical practice. Oral liquid preparations may be in the form of, for example, aqueous or oily suspensions, solutions, emulsions, syrups or elixirs, or may be presented as a dry product for reconstitution with water or other suitable vehicle before use.Such liquid preparations may contain conventional additives, such as suspending agents, for example sorbitol, methyl cellulose, glucose syrup, gelatin, hydroxyethyl cellulose, carboxymethyl cellulose, aluminium stearate gel or hydrogenated edible fats, emulsifying agents, for example lecithin, sorbitan monooleate, or acacia non aqueous vehicles which may include edible oils , for example almond oil, oily esters such as glycerine, propylene glycol, or ethyl alcohol preservatives, for example methyl or propyl p hydroxybenzoate or sorbic acid, and, if desired, conventional flavouring or colouring agents. Suppositories will contain conventional suppository bases, e.g. cocoa butter or other glyceride. For parenteral administration, fluid unit dosage forms are prepared utilizing the compound and a sterile vehicle, water being preferred. The compound, depending on the vehicle and concentration used, can be either suspended or dissolved in the vehicle. In preparing solutions the compound can be dissolved in water for injection and filter sterilised before filling into a suitable vial or ampoule and sealing.Advantageously, agents such as a local anaesthetic, preservative and buffering agents can be dissolved in the vehicle. To enhance the stability, the composition can be frozen after filling into the vial and the water removed under vacuum. The dry lyophilized powder is then sealed in the vial and an accompanying vial of water for injection may be supplied to reconstitute the liquid prior to use. Parental suspensions are prepared in substantially the same manner except that the compound is suspended in the vehicle instead of being dissolved and sterilization cannot be accomplished by filtration. The compound can be sterilised by exposure to ethylene oxide before suspending in the sterile vehicle. Advantageously, a surfactant or wetting agent is included in the composition to facilitate uniform distribution of the compound. The compositions may contain from 0.1 by weight, preferably from 10 60 by weight, of the active material, depending on the method of administration.Where the compositions comprise dosage units, each unit will preferably contain from 50 500 mg of the active ingredient. The dosage as employed for adult human treatment will preferably range from 100 to 3000 mg per day, for instance 1500 mg per day depending on the route and frequency of administration. The compound of formula I may be the sole therapeutic agent in the compositions of the invention or a combination with other antibiotics or with a lactamase inhibitor may be employed. Advantageously, the compositions also comprise a compound of formula X or a pharmaceutically acceptable salt or ester thereof EMI15.1 wherein A is hydroxyl, substituted hydroxyl, thiol, substituted thiol, amino, mono or di hydrocarbylsubstituted amino, or mono or di acylamino. A further advantageous composition comprises a compound of formula I or a pharamceutically acceptable salt or in vivo hydrolysable ester thereof together with a compound of formula XI or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof EMI16.1 The present invention also provides a method of treating bacterial infections in animals, in particular humans or domestic mammals, which comprises the administration of the composition of this invention The following Examples illustrate the preparation of the compounds of this invention. Example 1Sodium 6fB D 2 3 2 4 aminosulphonylghenylamino 4 hydroxypyrimidin 5 yl ureido 2 phenylacetamido 6,a methoxypenicillanate A suspension of 2 4 aminosulphonylphenylamino 5 amino 4 hydroxypyrimidine 0.28g, 1 mmol in freshly distilled, THF 50 ml with triethylamine at 0 C was treated with phosgene 1 ml of 12.5 w w solution in toluene, 1.1 mmol . After 15 minutes the reaction was allowed to gain room temperature, stirred for 30 minutes, evaporated to half volume and added dropwise to a solution of 6,I3 D 2 amino 2 phenylacetamido 6,a methoxypenicillanic acid 0.433g, 1 mmol in 60 aqueous THF 50 ml at pH 7.5 with triethylamine. The pH was maintained between 7.5 and 8.0 by additions of triethylamine over 1 hours.The THF was evaporated in vacuo and the aqueous residue washed with ether 2 x 50 ml , layered with ethylacetate 20 ml and the pH adjusted to 2.0 with 5N hydrochloric acid. The precipitated solid and the aqueous phase were discarded. The ethyl acetate phase was washed with water 3 x 20 ml , dried over magnesium sulphate, filtered and evaporated to dryness in vacuo. The gum was redissolved in acetone 20 ml and 2N sodium 2 ethylhexanoate in 4 methylpentan 2 one added until precipitation was complete. The solid was filtered off washed thoroughly with ether and dried in vacuo to yield 0.14 g, 19.8 . vmax KBr 3320 b , 1760, 1655, 1580, 1530, 1340, 1160 and 1100 cm l, 6 CD3 2S0,CD30D 1.02, 1.30 6H, 2 x s, 2 x 2CH3 , 3.45 3H, s, OCH3 , 4.06 1H, s, 3H , 5.42, 5.47 2H, 2 x s, 5H, CHCON , 7.15 8.05 9H, m, Ph, Ar, , 8.26 1H,s, pyrimidin 3H . Antibacterial activity MIC pg ml EColi JT 425, 2.5 Ps aeruginosa 10662, 50 Klebsiella aerogenes A, 2.5 P mirabilis C977, 2.5 Staph. aureusOxford, 10. Example 2Sodium 6B D 2 3 4 hydroxy 2 phenylamino pyrimidin 5 yl ureido 2 phenylacetamido 6a methoxy penic illanate 6B D 2 Amino 2 phenylacetamido 6a methoxy penicillanic acid trihydrate 0.39 g, 0.9 mmol was suspended in water 10 ml and tetrahydrofuran 20 ml . The pH of the mixture was adjusted to 7.5 with triethylamine and the resulting solution treated portionwise with N 4 hydroxy 2 phenylamino pyrimidin5 yl carbamoyl chloride 0.24 g, 0.9 mmol , the pH of the mixture being maintained between 7 and 7.5 by addition of triethylamine. After 0.5 h at room temperature, the tetrahydrofuran was evaporated in vacuo, the aqueous residue washed with ethyl acetate 30 ml , diethyl ether 30 ml and covered with a layer of ethyl acetate 30 ml . The pH of the aqueous phase was adjusted to 2 by addition of 5M hydrochloric acid, the phases separated, the aqueous phase further extracted with ethyl acetate 2 x 20 ml , the extracts combined, washed with water at pH2 20 ml , water 20 ml and saturated brine 20 ml , before drying over anhydrous magnesium sulphate.Evaporation of the solvent in vacuo, gave a yellow powder 0.34 g, 62 , which was dissolved in acetone 20 ml and methanol 2 ml and the resulting solution treated with 2M sodium 2 ethylhexanoate in 4 methylpentan 2 one 0.28 ml, 0.56 mmol followed by diethyl ether 100 ml . The precipitate was collected by filtration, washed with ether and dried in vacuo to yield the title compound, 0.305g, 53 , max KBr 3330b, 1760, 1657b, 1600b, 1540b, 1498, 1443, 1390, 1372, 1340, 1255sh, 1211 and 1100 cm l 6 CD3 2S0 1.00 and 1.29 6H, 2s, 2x2CH3 , 3.40 3H, s, OCH3 , 3.91 1H, s, 3 H , 5.35 1H, s, 5 H , 5.52 1H, d J 8Hz, CH , 6.76 7.92 12H, m, 2xPh and 2 x NH , 8.18 2H, bs, pyrimidine proton and NH , 9.57 1H, bs, CONH , 10.90 1H, bs, OH .Antibacterial activity MIC pg ml E Coli JT 425, 12.5 Klebsiella aerogenes A, 5 P mirabilis C977, 12.5 Staph. aureusOxford, 12.5. Example 3Sodium 6,ss D,L 2 3 2 4 aminosulfonylphenylamino 4 hydroxypyrimidin 5 yl ureidol 2 4 hydroxyphenyl acetam ido 6, alpha methoxypenicillanate i Benzyl 6,ss D,L 2 3 2 4 benzyloxycarbonphenylamino 2 4 nitrobenzyloxycarbonylamino acetamido 6 alpha methylthio penicillanate.D 2 4 Benzyloxycarbonyloxyphenyl 2 4 nitrobenzyloxy carbonylamino acetic acid 4.80g 10mmol in dry dichloromethane 50m1 was treated with oxalyl chloride 1.Oml and dry DMF 5 drops at room temperature.After 1 hour the solvent was removed in vacuo and the residue redissolved in dry THT 20m1 . This solution was added dropwise, at 0 SOC, to a solution of benzyl 6ss amino 6 alpha methylthiopenicillanate 3.52g lOmmol inTHF 20ml containing pyridine 0.8ml 10mmol . Stirred at 0 50C for 0.5 hours and allowed to regain room temperature over a further 0.5 hours. The reaction mixture was then evaporated to dryness in vacuo and the residue treated with ethyl acetate 100ml and water 100ml . The phases were separated and the organic phase washed with water 50ml , saturated brine 25ml , dried over anhydrous magnesium sulphate and evaporated to dryness in vacuo to yield a yellow foam.Crystallisation from ethyl acetate cyclohexane gave the title compound 4.14g 51 yield as a white,crystalline solid, m.p 103 1050C, a 0 46.30 C l in CHC13 , vmax KBr 3000b, 1775, 1760, 1740, 1670, 1515, 1348, 1240b, 1053 and 700cm 1, CDCl3 , 0.95 and 1.21 6H, 2xs, 2x2CH3 , 2.25 3H,s, SCH3 , 4.33 lH,s,3 H , 5.17 and 5.25 6H,2xs, 2x2CH2Ph and CH2C6H4 , 5.45 5.70 2H,m,5 H and CH , 6.41 lH,dJ7HzNHCH , 6.98 7.64 and 8.10 8.35 19H,m, 4xAr and CONH .Found C,59.03, H, 5.12 N, 6.52 S,7.69 .C40H38N4011S2 requires C,58.97 H, 4.67 N, 6.88 S, 7.86 . ii Benzyl16ss D 2 4 benzyloxycarbonyloxyphenyl 2 4 nitrobenzyloxycarbonylamino acetamido 6 alpha methoxypenicillanate.Benzyl 6B D 2 4 benzyloxycarbonyloxyphenyl 2 4 nitrobenzyloxycarbonylamino acetamido 6a methylthiopenicillanate 1.58g 1.9mmol was suspended in methanol 150ml . Just sufficient DMF was added to obtain complete solution when mercuric acetate 0.61g 1.9mmol was added. After 0.5hours at room temperature, the mixture was filtered and the filtrate evaporated to dryness in vacuo to yield an off white foam, which was treated with ethyl acetate 150ml and water 50m1 . The phases were separated and the organic phase washed with water 3x50m1 , brine 50ml , dried over anhydrous magnesium sulphate and evaporated to dryness in vacuo to yield a white powder.Recrystallisation from ethyl acetate cyclohexane gave the product 1.39g 90 , m.p 107 109 C, vmax KBr 3410, 3310, 1765, 1690, 1520, 1500, 1350, 1240, 1100, and 1050cm 1, 6 CDC13 0.87 and 1.18 6H, 2xs, 2x2 CH3 , 3.43 3H,s,OCH3 , 4.28 1H,s,3 H , 5.13 and 5.21 6H, 2xs, 2xCH2C6Hs and CK2C6H4 , 5.45 1H,d,J8Hz,CH , 5.55 1H,s,5 H , 6.30 1H,d J8Hz, NHCH , 7.00 7.57 and 8.09 8.26 19H,m,aromatics and CONH . Found C, 58.74 H, 4.98 N, 6.85 S, 4.41 . C40H38N4012S requires C,60.15 H, 4.76 N,7.02 S, 4.01 . iii 6ss D 2 Amino 2 4 hydroxyphenyl acetamido 6 alpha methoxypenicillanic acid.Benzyl 6B D 2 4 benzyloxycarbonyloxyphenyl 2 4 nitrobenzyloxycarbonylamino acetamido 6a methOxy penicillanate 1.3g 1.63mmol was dissolved in THF 25ml and the soluton diluted with ethanol lOOml .Hydrogenation at atmospheric pressure and room temperature was accomplished over 10 palladium on charcoal in 1 hour. The catalyst was removed by filtration and the filtrate concentrated to low volume in vacuo and the residue diluted with ether 100ml . The resulting solid was filtered, washed with ether and dried in vacuo 0.49g 76 , max KBr 3700 2200b, 1760, 1680, 1600b, 1515, 1255b, and llO0cm1, 6 CD3 2SO 0.95 and 1.28 6H,2xs, 2x2 CH3 , 3.39 3H,s,OCH3 , 4.02 1H,s,3 H , 4.81 1H,bs,CH , 5.32 1H,s,5 H , 6.75 and 7.34 4H,2d J9Hz, C6H4 .iv Sodium 6, D 2 3 2 4 aminosulphonyl phenylamino 4 hydroxypyrimidin 5 yl ureido 2 4 hydroxyphenyl acetamido 6,a methoxypenicillanate A suspension of 2 4 aminosulphonylphenylamino 5amino 4 hydroxypyrimidine 0.28g, lmmol in freshly distilled THF 50 ml with triethylamine 0.14 ml, 1 mmol at 0 C was treated with phosgene 1 ml of 12.5 w w solution in toluene, 1.1 mmol . After 15 minutes the reaction was allowed to gain room temperature, stirred for 30 minutes and added dropwise to a solution of 6,3 D 2 amino 2 4 hydroxyphenyl acetamido 5,a methoxypenicillanate 0.419g, 1 mmol in 60 aqueousTHF 50 ml at pH 7.5 with triethylamine. The pH was maintained between 7.5 and 8.0 by additions of triethylamine over 1.5 hours. The THF was evaporated in vacuo and the aqueous residue washed with ether 2x50 ml , layered with ethyl acetate 20 ml and the pH adjusted to 2.0 with 5N hydrochloric acid. The precipitated solid and the aqueous phase were discarded. The ethyl acetate phase was washed with water 3x20 ml , dried over magnesium sulphate, filtered and evaporated to dryness in vacuo. The gum was redissolved in acetone 10 ml and 1.85 N sodium 2 ethylhexanoate in 4 methylpentan 2 one added until precipitation was complete. The solid was filtered off, washed thoroughly with acetone, ether and dried in vacuo and chromatographed on silica gel eluting with ethyl acetate, ethanol, water 6 2 1 to yield 16 mg. v max KBr 3450 b , 1760, 1655, 1590, 1530, 1340 and 1155 cm l 5 CD3 2SO, CD30D 1.00, 1.28 6H, 2xs, 2x2CH3 , 3.41 3H, s, OCH3 , 3.97 1H, s, 3H 5.31 1H, s, CHCON , 5.35 1H, s, 5H , 6.70, 7.28 4H, ABq,Antibacterial activity MIC pg ml E Coli JT 425, 2.5 Ps aerugimosa 10662, 25 Klebsiella aerogenes A, 0.2 P mirabilis C977, 1.25 Staph, aureus Oxford, 50.EMI23.1 7.72, 7.76 4H, ABq, JlOHz, 1H, s, pyrimidin 3H . Example 4Sodium 6ss D 2 Amino 3 2 4 aminosulphonylphenylamino 4hydroxy pyrimidin 5 yl 2 thien 2 yl acetamido 6, a methoxypenicillanate. i Benzyl 6a methylthio 6B DL 2 4 nitrobenzyloxy carbonylamino 2 thien 2 yl acetamido penicillanate.DL 2 4 Nitrobenzyloxycarbonylamino 2 thien 2 yl acet ic acid 3.36g lOmmol was suspended in dry dichloromethane 25ml and treated at room temperature with oxalyl chloride 1.0ml and dry DMF 3 drops .After 1 hour at room temperature, the reaction mixture was evaporated to dryness in vacuo and the residue redissolved in dry THF 15ml . Benzyl 6B amino 6a methylthiopenicillanate 3.52g lOmmol was dissolved in THF 15ml containing triethylamine 1.4ml lOmmol and the mixture treated at room temperature with the acid chloride solution. After 1 hour at room temperature, the reaction was filtered.The filtrate was evaporated to dryness in vacuo and the resulting yellow foam chromatographed on silica gel eluting with 10 ethyl acetate in cyclohexane grading to 20 ethyl acetate in cyclohexane to yield 5.18g 77 as a foam, 9max KBr 3400, 3300b, 1780, 1740, 1680, 1520, 1347, 1320, 1310, 1230b, 1205, 1055 and 700cm 1, 6 CDC13 1.10, 1.24, 1.30 and 1.35 6K, 4xs, 2x2 CH3 , 2.02 and 2.20 3K, 2xs, SCH3 , 4.35 and 4.40 1H, 2xs, 3 H , 2.10 2.27 4H,m,CH2C6H5 and CH2C6H4 , 5.53 1H,s,5 H , 5.70 5.95 1H,m,NHCH , 6.31 lH,dJ8Hz,NHCH , 6.81 7.60 and 8.03 8.28 12H,2m, thienyl, C6H4 and C6Hs , 7.75 1H,b, CONH . Found M 670.1194. C30K30N408S3 requires 670.1225. ii Benzyl 6 alpha methoxy 6ss D and L 2 4 nitrobenzyloxy carbonylamino 2 thien 2 yl acetamido penicillanateBenzyl 6 alpha methylthio 6ss DL 2 4 nitrobenzyloxy carbonyl amino 2 thien 2 yl acetamido penicillanate 3.52 g 5.25 m mol in methanol 100 ml , was treated at room temperature with mercuric acetate 1.67 g 5.25 m mol . After 0.5 hours, the reaction mixture was diluted with ethyl acetate 200 ml , filtered and washed with water 100 ml , saturated brine 100 ml , dried over anhydrous magnesium sulphate and evaporated to dryness in vacuo.Preparative high performance liquid chromatography Waters prep 500 machine, Waters prep pak 500 silica column and 30 ethyl acetate in cyclohexane as eluent gave the D diasteroisomer 1.09 g 32 as a foam, alpha b20 100.3 C 1 in chloroform , vmax RBr 3310 b, 1775, 1742, 1685, 1520, 1348, 1320, 1260, 1240, 1206, 1100, 1055 and 700 cm l, 6 CDCl3 1.08, 1.25 6H, 2xs, 2x2 CH3 , 3.42 3H, s, OCH3 , 4.35 1H, s, 3 H , 4.15 and 4.22 4H, 2xs, CH2C6Hs andCH2C6H4 , 5.59 1H, s, 5 H , 5.83 1H, d, 3 8 Hz, CHNH , 6.29 1H, d J8Kz, CHNH , 6.80 7.00, 7.13 7.58, 8.00 8.25 12H, 3m, C6Hs, C6H4 and thienyl protons , 7.60 8.00 1H, bs, CONH .Found M 654.1405. C30H30N4O9S2 requires 654.1454.Also obtained was the L diastereoisomer 0.97 g 28 , alpha b20 171.80 C l in chlorofor , vmaX KBr 3400b, 3320b, 1780, 1740, 1690, 1520, 1347, 1205, 1102, and 700 cm 1 6 CDC13 1.31 and 1.36 6H, 2xs, 2x2 CH3 , 3.28 3H, s, OCH3 , 4.40 1H, s, 3 H , 5.17 4H, s,CH2C6H5 and CH2C6H4 , 5.53 1H, s, 5 H , 5.59 1H, d J 7Hz, CH , 6.13 1H, d J 7Hz, NHCH , 6.88 7.60 and 8.05 8.28 13H, m, C6H4, C6H5, thienyls, CONH . Found M 654.1399. C30H30N409S2 requires M 654.1454. iii 6ss D 2 Amino 2 thien 2 yl acetamido 6 alpha methoxypenicillanic acidBenzyl 6 alpha methoxy 6ss D 2 4 nitrobenzyloxycarbonyl amino 2 thien 2 yl acetamido penicillanate 1.0 g, 1.5 m mol was dissolved in THF minimum , the solution diluted to turbidity with water then diluted to a clear solution by addition of ethanol.Hydrogenation over 10 palladium on charcoal at room temperature and atmospheric pressure for 2 hours, followed by filtration and evaporation to dryness in vacuo gave a crude product, which was triturated under a mixture of propan 2 ol 5 ml and diethyl ether 20 ml and the resulting solid collected by filtration, washed with ether and dried in vacuo 0.27 g 46 , max KBr 3700 2200 b, 1760, 1700, 1605, 1525b, 1400, 1370, 1345, 1250 and 1095cm 1, 6 CD3 2SO 1.15 and 1.31 6H, 2xs, 2x2 CH3 , 3.37 3H, s, OCH3 , 4.10 1H, s, 3 H , 4.97 1H, s, CH , 5.32 1H, s, 5 H , 6.90 7.05, 7.15 7.28, 7.35 7.50 3H, 3m, thienylprotons .iv Sodium 6, D 2 3 2 4 aminosulphonylphenyl amino 4 hydroxypyrimidin 5 yl ureido 2 thien 2 yl acetamido 6 alpha methoxypenicillanate. Prepared by the method described in example 1 except that 6, D 2 amino 2 thien 2 yl acetamido 6a methoxypenicillanic acid 0.385 g, 1 m mol was used.The product was chromatographed on silica gel eluting with ethyl acetate, ethanol, water 6 2 1 to yield 70 mg, vmaX KBr 3320 b , 1765, 1655, 1590, 1535 b and 1155 cm 1, 6 CD3 2SO,CD3OD 1.19, 1.37 6H, 2xs, 2x2 CH3 , 3.43 3H, s, OCH3 , 4.06 1H, s, 3H , 5.47 1H, S, 5H , 5.78 1H, s, CHCON , 6.89 7.50 3H, m, thienyl 3,4 and 5H 7.79 4H,EMI26.1 8.30 1H, s, pyrimidin 3H . Example 5Sodium 6,B L 2 3 2 4 aminosulphonylphenylamino 4 hydroxy pyrimidin 5 yllureido 2 thien 2 y acetaido 6a methoxypenicillanate i 6B L 2 Amino 2 thien 2 yl acetamido 6a methoxypenicillanic acidBenzyl 6a methoxy 6B L 2 4 nitrobenzyloxycarbonyl amino 2 thien 2 yl acetamido penicillanate 0.43 g 0.66 m mol from example 4ii was dissolved in minimumTHF, the solution diluted to turbidity with water then diluted with ethanol to give a clear solution.Hydrogenation was carried out over 10 palladium on charcoal at room temperature and atmospheric pressure.After 4 hours, the catalyst was removed by filtration, the filtrate concentrated in vacuo, washed with chloroform, filtered through Celite and evaporated to dryness in vacuo 0.24 g, 968 , vmaX KBr 3800 2400, 1768, 1670 b , 1600 b , 1510, 1250, 1170 and 1110 cm 1, 6 CD3 2SO 1.42 6H, s, 2x2 CH3 , 3.22 3H, s,OCH3 , 4.16 1H, s, 3 H , 4.85 1H, s, CH , 5.38 1H, s, 5 H , 6.90 7.05, 7.08 7.20 and 7.32 7.50 3K, 3m, thienyl protons.ii Sodium 6,3 L 2 3 2 4 aminosulphonylpheny lamino 4 hydroxy pyrimidin 5 yl ureido 2 thien 2 yl acetamido 6, alpha methoxypenicillanate Prepared by the method described in example 1 except 6, L 2 amino 2 thien 2 yl acetamido 6, methoxy penicillanic acid 0.385 g, lmmol was used.The product was chromatographed on silica gel eluting with ethyl acetate, ethanol, water 6 2 1 to yield 110 mg Vmax KBr 3350 b , 1765, 1660, 1590, 1530 b and 1155 cm 1, 6 CD3 2SO CD3OD 1.47 6H, s, 2x2CH3 , 3.26 3H,s,OCH3 , 4.13 1H, s, 3H , 4.48 1H, s, 5H , 5.87 1H, s, CHCON , 6.90 7.45 3H, m, thienyl 3,4 and 5H , 7.78, 7.84 4H, ABq JlOHz,EMI28.1 8.30 1H, s, pyrimidin 3H Example 6Sodium 6,ss D,L 2 3 2 4 aminosulfonylphenylamino 4 hydroxypyrimidin 5 yll ureidol 2 furan 2 yl acetamido 6, alpha methoxy penicillanate i Benzyl 6,ss D,L 2 benzyloxycarbonylamino 2 fur 2 yl acetamido 6, alpha methylthiopenicillanate 2 Benzyloxycarbonylamino 2 fur 2 yl acetic acid 1.38 g, 5 mmol in dichloromethane 15 ml was added dropwise over 30 minutes to an ice bath cooled solution of benzyl 6,ss amino 6, alpha methylthiopenicillanate 1.94 g 5.5 mmol and DCC 1.13g 5.5 mmol in dichloromethane 30 ml . The mixture was stirred overnight then filtered and the filtrate evaporated to dryness.The residue was chromatographed on silica gel eluting with 20 ethyl acetate in cyclohexane to give the title compound, 2.37 g 77.8 yield, 6 CDC13 1.20, 1.25, 1.32, 1.42 6H, 4xs, 2x2 CH3 , 2.08, 2.22 3K, 2xs, SCK3 , 4,36, 4.41 1H, 2xs, 3H , 5.08, 5.12 4H, 2xs, 2xOCH2Ph , 5.50 1H, s, 5H , 5.5 5.9 1H, m, CHCONH , 6.0 6.4 3H, m, furan 3H and 4H, NHCO , 7.1 7.4 11H, m, 2xPh, furan 5H , 7.90 8.05 1H, 2xs, CONH .ii Benzyl 6,ss D,L 2 benzyloxycarbonylamino 2 fur 2 yl acetamido 6 alpha methylthiopenicillanate Mercuric acetate 1.24 g 3.89 mmol was added to benzyl 6, D,L 2 benzyloxycarbonylamino 2 fur 2 yl acetamido 6,a methylthiopenicillanate 2.37 g, 3.89 mmol in methanol .20 ml .After 20 minutes ethyl acetate 150 ml was added and the solution washed with water 3 x 50 ml and brine 25 ml , dried and evaporated to a foam which was chromatographed on silica gel eluting with 20 ethyl acetate in cyclohexane to give the title compound, 1.87 g, 83.2 yield 6 CDC13 1.17, 1.25, 1.30, 1.37 6H, 4xs, 2x2CH3 , 3.30, 3.43 3K, 2xs, OCH3 , 4.40, 4.43 1H, 2xs, 3H , 5.13, 5.15 4H, 2xs, 2xOCH2Ph , 5.60 1H, s, 5H 5.5 5.9 1H, m, CH2CONH , 6.2 6.5 3H, m, furan 3H and 4H, NHCO , 7.1 7.5 11H, m, 2xPh, furan 5H , 8.00, 8.28 1H, 2xs, CONH .iii 6,ss D,L 2 Amino 2 fur 2 yl acetamido 6, alpha methoxypenicillanic acidBenzyl 6, D,L 2 benzyloxycarbonylamino 2 fur 2 yl acetamido 6,amethoxypenicillanate 1.86 g in ethanol 25 ml was diluted with water until almost cloudy then hydrogenated in the presence of 10 palladium on carbon 1.85 g for 30 minutes. The solution was filtered, concentrated in vacuo and freeze dried to give the title compound, 0.90 g, 77.8 yield, vmaX KBr 1765, 1705, 1600, 1250, and 1092 cm l, 6 D20 1.20, 1.37, 1.42, 1.49 6H, 4xs, 2x2CH3 3.40, 3.55 3H, 2xs,OCH3 , 4.25, 4.30 1H, 2xs, 3H 5.4 5.7 2H, m, 5H,CHCONH , 6.5 6.9 and 7.7 7.9 3H, m, furan .iv Sodium 6, D,L 2 3 t4 aminosulphonylphenyl amino 4 hydroxy pyrimidin 5 yl ureido 2 furan 2 furan 2 yl acetamido 6,u methoxypenicillanate A suspension of 2 4 aminosulphonylphenylamino 5amino 4 hydroxy pyrimidine 0.84g, 3 mmol in freshly distilled THF 70 ml with triethylamine 0.42 ml, 3 mmol at 0 C was treated with phosgene 3 ml of 12.5 w w solution in toluene, 3.3 mmol . After 1 hour the reaction was evaporated to half volume and added dropwise to a solution of 6, D,L 2 amino 2 furan 2 yl acetamido 6,a methoxy penicillanic acid 0.524 g, 1.42 mmol in 70 aqueous THF 50 ml at pH 7.5. The pH was maintained between 7.3 and 7.8 by addition of triethylamine over 1 hours. The mixture was washed with ether 3x50 ml , filtered, layered with ethyl acetate 70 ml and acidified to pH 2.0 with 5N hydrochloric acid. The organic phase was collected and the aqueous extracted with ethyl acetate 2x60 ml .The combined organic phases were washed with water 3x100 ml , dried over magnesium sulphate, filtered and evaporated to dryness in vacuo. The gum was redissolved in acetone 10 ml and 1.85 N sodium 2 ethylhexanoate in 4 methylpentan 2 one added until precipitation was complete. The solid was filtered off, washed thoroughly with ether and dried in vacuo to yield 0.3 g, vrnax KBr 3300 b , 1765, 1655, 1600 b , 1530 b , 1405, 1335 and 1155 cm l, 6 CD3 2SO D2O 1.23, 1.37, 1.42 6H, 3xs, 2x2CH3 , 3.27, 3.42 3H, 2xs, OCH3 1 4.01, 4.04, 1H, 2xs, 3H , 5.43 1H, s, soh , 5.62, 5.67 1H, 2xs, CHCON , 6.50 2H, m, furan 3,4H , 7.61 1H, m, furan 5H , 7.77, 7.87 4H, ABq, J9Hz, 8.28. 1H, s, pyrimidin 3H .EMI31.1 Example 7Sodium 6,ss D,L 2 3 2 4 aminosulfonylphenylamino 4 hydroxypyrimidin 5 yl ureido 2 2 fluorophenyl acetamido 6, alpha methoxypenicillanate i Benzyl 6,ss D,L 2 2 fluorophenyl 2 4 nitro benzyloxycarbonylamino acetamido 6, alpha methyl penicillanate A suspension of D,L 2 2 fluorophenyl 2 4 nitrobenzyloxycarbonylamino acetic acid 5.8 g, 16.7 mmol in dry dichloromethane 150 ml was treated with oxalyl chloride 1.6 ml and DMF 4 drops . After 1 hour at room temperature the clear solution was evaporated to dryness in vacuo. max CHC13 3440, 1795, 1730, 1495 and 1350 cm 1. The acid chloride was dissolved in THF 30 ml and added dropwise to a solution of benzyl 6, amino 6, methylthiopenicillanate 6.45 g, 18.3 mmol and pyridine 1.6 ml in THF 100 ml at OOC. The reaction was allowed to gain room temperature, stirred for 1 hour, diluted with ethyl acetate 250 ml , washed with water 5 x 100 ml , brine 100 ml , dried over magnesium sulphate, filtered, evaporated and chromatographed on silica gel eluting with 40 ethyl acetate and cyclohexane to yield 9.5 g, 84.1 , max CHC13 3410, 1795, 1745, 1735, 1695, 1590 and 1350 cm 1, 6 CDC13 0.95, 1.17, 1.36, 1.55 6H, 4 x s, 2x2CH3 , 2.02, 2.23 3H, 2 x s, 5CH3 , 4.33, 4.44 1H, 2 x s, 3H , 5.20 4H, S, 2 xOCH2 , 5.37, 5.50 2H, 2 x s, CHCON, 5H , 5.75, 6.37 2H, b, 2 x NH , 6.90 8.25 13H, m, 3 x Ar . ii Benzyl 6,ss D,L 2 2 fluorophenyl 2 4 nitro benzyloxycarbonylamino acetamido 6, alpha methyloxy penicillanate A solution of 6, D,L 2 2 fluorophenyl 2 4 nitrobenzyloxycarbonylamino acetamido 6,a methylthiopenicillante 9.4 g, 13.8 mmol in methanol 120 ml at room temperature was treated with mercuric acetate 4.3 g, 13.5 mmole in methanol 60 ml . After 20 minutes the mixture was filtered, evaporated to low volume, dissolved in ethyl acetate 200 ml , washed with water 3 x 200 ml , brine 200 ml , dried over magnesium sulphate, filtered and evaporated to dryness in vacuo.Chromatographed on silica gel eluting with 40 ethyl acetate in cyclohexane to yield 4.6 g, 50.1 . 9max CKCl3 1785, 1740, 1750, 1495 and 1350cm 1, 6 CDC13 0.94, 1.26, 1.33, 1.36, 1.44 6H, 4 x s, 2 x 2CK3 , 3.25, 3.48 3H, 2 x s, OCH3 , 4.35, 4.46 1H, 2 x s, 3H , 5.20 4H, s, 2 x OCH2 , 5.56 1H, s, 5H , 5.73, 5.88 1H, bd, J7Hz, CHCON , 6.33, 6.47 1H, d,J7Hz, CHNH , 6.90 8.25 14H, m, 3 x Ar, CONH .iii 6, ED,L 2 amino 2 2 fluorophenZl acetamidol 6, methoxypenicillanic acid A solution of benzyl 6, D,L 2 fluorophenyl 2 4 nitrobenzyloxycarbonylamino acetamido 6,a methOxy penicillante 4.2 g in THF 10 ml , ethanol 100 ml , water 10 ml was hydrogenated at ambient temperautre and pressures for 1 hour in the presence of 10 Pd C 4.5 g . After filtering the solution was evaporated to low volume and the remainder freeze dried.The solid was dissolved in methanol 5 ml , filtered, precipitated with ether, filtered, washed thoroughly with ether and dried in vacuo to yield 1.5g. max KBr 3350 b , 1765, 1700, 1600, 1595, 1235 and 760cm l. 6 D2O 0.98, 1.13, 1.22, 1.32 6H, 4xs, 2x2CH3 , 3.22, 3.41 3H, 2xs, OCH3 , 4.07, 4.14 1H, 2 x s, 3H , 5.4, 5.45 2H, 2 x s, 5H, CHCON , 7.03 7.8 4H, m, Ar .iv Sodium 6,ss D,L 2 3 2 4 aminosulfonylphenyl amino 4 hydroxypyrim n 5 yl ureido 2 2 fluorophenyl acetamido 6, alpha methoxypenicillante. A suspension of 2 4 aminosulphonylphenylamino 5 amio 4 hydroxypyrimidine 1.12 g, 4 mmol in freshly distilled THF 100 ml with triethylamine 0.56 ml, 4 mmol at 0 C was treated with phosgene 4 ml of 12.5 w w solution in toluene, 4.4 mmol . After 15 minutes the reaction was allowed to gain room temperature, stirred for 30 minutes, evaporated to half volume and added dropwise to a solution of 6, D,L 2 amino 2 2 fluorophenyl acetamido 6 alpha methoxy penicillanic acid 0.8 g, 2 mmol in 60 aqueous THF 100 ml at pH 7.5 with triethylamine. The pH was maintained between 7.3 and 7.8 by additions of triethylamine over 1L hours.The THF was evaporated in vacuo and the aqueous residue washed with ether 2 x 100 ml , layered with ethyl acetate 150 ml and the pH adjusted to 2.0 with 5N hydrochloric acid. The precipitated solid and the aqueous phase were discarded. The ethyl acetate phase was washed with water 2 x 100 ml , brine 100 ml , dried over magnesium sulphate, filtered and evaporated to dryness in vacuo. The gum was redissolved in acetone 30 ml and 1.8501 sodium 2 ethylhexanoate in 4 methylpentan2 one added until precipitation was complete. The solid was filtered off, washed thoroughly with acetone, ether and dried in vacuo and chromatographed on silica gel eluting with ethyl acetate, ethanol, water 5 2 1 to yield 300 mg. Umax KBr 3350 b , 1765, 1655, 1590, 1530, 1335 and 1155cm l. 6 CD3 2SO,D2O 1.09, 1.34, 1.42 6H, 3 x s, 2 x 2CH3 , 7.2, 7.40 3H, 2 x s, OCH3 , 3.98, 4.05 1H, 2 x s, 3H , 5.38 1H, s, 5K , 5.73, 5.78 1H, 2 x s, CHCON , 7.05 7.60 4H, m, Ar 7.64, 7.90 4H, ABq,JlOHz,EMI35.1 8.23 1H, s, pyrimidin 3H . Example 8Sodium 6,ss D,L 2 3 2 4 aminosulfonylphenylamino 4 hydroxy pyrimidin 5 yl ureido 2 4 fluorophenyl acetamido 6, alpha methoxypenicillanic. i Benzyl 6,ss 2 4 fluorophenyl 2 4 nitrobenzyl oxycarbonylamino acetamido 6, alpha methylthio penicillanate Oxalyl chloride 0.95 ml and DMF 3 drops were added to a solution of N 4 nitrobenzyloxycarbonyl2 4 fluorophenyl glycine 3.48 g, 10 mmol in anhydrous dichloromethane 100 ml . The solution was stirred for 1 hour than evaporated to dryness. vmax film 1787cm l COC1 . The residue was dissolved inTHF 20 ml and added dropwise to an ice bath cooled solution of benzyl 6, amino 6,a methylthiopenicillante 3.87 g, 11 mmol and pyridine 0.95 ml in THF 100 ml .When the addition was complete the mixture was stirred at room temperature for one hour then diluted with ethyl acetate 200 ml , washed with water 5x100 ml and brine 100 ml , dried and evaporated to a foam. The title compound was isolated by chromatography on silica gel eluting with 20 ethyl acetate in cyclohexane, 3.22 g, 47 .ii Benzyl 6,ss 2 4 fluorophenyl 2 4 nitrobenzyl oxycarbonylamino acetamido 6, alpha methoxy penicillanate. Benzyl 6,13 2 4 fluorophenyl 2 4 nitrobenzyloxy carbonylamino acetamido 6, alpha methylthiopenicillanate 3.22g in methanol 20 ml and ethyl acetate 20 ml was treated with mercuric acetate 1.50g . The mixture was stirred for one hour, diluted with ethyl acetate 150 ml , and filtered.The filtrate was washed with water 3x100 ml and brine 100 ml , dried and evaporated to a foam which was chromatographed on silica gel eluting with 20 ethyl acetate in cyclohexane to give the title compound, 2.91 g, 93 , CD3 2CO 1.10, 1.26, 1.38, 1.50 6H, 4 x S, 2 x 2CH3 , 3.20, 3.45 3H, 2 x s, OCH3 , 4.40, 4.48 1H, 2 x s, 3H , 5.23 4K, s, 2 x OCH2 , 5.46, 5.48 1H, 2 x s, 5H , 5.4 5.7 1H, m, CHCONH , 6.9 8.3 14H, m,Ar, NHCO2 , 8.68 1H, s, CONH .iii 6,b 2 Amino 2 4 fluorophenyl acetamido 6 Q methoxypenicillanic acid Benzyl 6,ss 2 4 fluorophenyl 2 4 nitrobenzyloxycarbonylamino acetamido 6,a methxypenicillanate 2.75g was dissolved in THF 35 ml , diluted with water until just not cloudy then hydrogenated in the presence of 10 palladium on carbon 2.75g for 2.5 hours. The mixture was filtered through celite and the filtrate concentrated in vacuo.The aqueous residue was washed with ethyl acetate 2 x 50 ml and ether 30 ml and freeze dried, 0.72 g, 44 , vmaX KBr 1765, 1695, 1605, 1570, 1230 and 1095cm l. 6 D20 0.85, 1.13, 1.28, 1.37 6H, 4 x s, 2 x 2CH3 , 3.24, 3.46 3H, 2 x s, OCH3 , 4.09, 4.16 1H, 2 x s, 3H , 5 15, 5.22 1H, 2 x S, CHCONH , 5.45, 5.49 1H, 2 x s, 5H , 7.0 7.7 4H, m, Ar .iv Benzyl 6,ss D,L 2 3 2 4 aminosulfonylphenyl amino 4 hydroxypyrimidin 5 yl ureido 2 4 fluorophenyl acetamido 6, alpha methoxypenicillanate A suspension of 2 4 aminosulphonylphenylamino 5amino 4 hydroxypyrimidine 0.56g, 2 mmol in freshly distilled THF 80 ml with triethylamine 0.28 ml, 2 mmol at 0 C was treated with phosgene 2 ml of 12.5 w w solution in toluene, 2.2 mmol . Stirred for 1 hour, evaporated to half volume in vacuo and added dropwise to a solution of 6,B D,L 2 amino 2 4 fluoro phenyl acetamido 6,a methoxypenicillanic acid 0.4 g, 1 mmol in 70 aqueous THF 70 ml at pH 7.5 with triethylamine. Allowed to warm to room temperature and stirred for 2 hours. The pH was maintained between 7.3 and 7.8 by additions of triethylamine.The mixture was washed with ether 3 x 100 ml , filtered and acidified to pH 2 with 5N hydrochloric acid. The aqueous was extracted with ethyl acetate 3 x 80 ml . The combined extracts were washed with water 3 x 50 ml , dried over magnesium sulphate, filtered and evaporated to dryness in vacuo. The gum was dissolved in acetone 20 ml and 1.85 N sodium 2 ethylhexanoate in 4 methylpentan 2 one 0.2ml was added.The solid was filtered off, washed thoroughly with acetone, ether and dried in vacuo to yield 260 mg, 17.1 . max KBr 3350 b , 1760, 1655, 1600, 1550, 1410 and 1155cm l, 6 CD30D CD3 2SO 1.03, 1.36, 1.41, 1.48 6H, 4 x s, 2 x 2CH3 , 3.45, 3.54 3H, 2 x s, OCH3 , 3.98, 4.08 1H, 2 x s, 3H , 5.44, 5.52, 5.58, 5.63 2H, 4 x s, 5H, CHCON , 6.90 8.05 8H, m, 2 x Ar , 8.29 1H, s, pyrimidin 6H . Example 9Sodium 6,ss D,L 2 3 2 4 aminosulfonylphenylamino 4 hydroxypyrimidin 5 yljureidol 2 3,4 diacetoxyphenyl acetamido 6, alpha methoxypenicillanate i Benzyl 6, D,L 2 3,4 diacetoxyphenyl 2 4 nitrobenzyloxycarbonylamino acetamido 6, alpha methoxypenicillanate Prepared by the method described in example 4, ii except that benzyl 6,ss D,L,2 3,4 diacetoxyphenyl 2 4 nitrobenzyloxycarbonylamino acetamido 6,a methylthiopenicillanate 4.81g, 6.17 mmol and mercuric acetate 1.97 g, 6.17 mmol in methanol 70 ml were used.The product was chromatogrpahed on silica gel eluting with 508 ethyl acetate in cyclohexane to yield 4.82 g, 97.2 , CDC13 0.89, 1.28, 1.33 6H, 3 x S, 2 x 2CH3 , 2.30 6H, s, 2 x COCH3 , 3.23, 3.50 3H, 2 x s, OCH3 , 4.40, 4.47 1H, 2 x s, 3H , 5.28 4H, S, 2 x OCH2 , 5.68 2H, bs, 5H, CHCON , 6.5 8.4 14H, m, 2 x CONH, 3 x Ar . ii 6,ss D,L 2 Amino 2 3,4 diacetoxyphenyl acetamido 6,a methoxypenicillanate A solution of benzyl 6,B D,L 2 3,4 diacetoxyphenyl 2 4 nitrobenzyloxycarbonylamino 6,a methoxypenicillanate 4.55 g in THF 30 ml , ethanol 100 ml and water 20 ml was hydrogenated at atmospheric pressure and room temperature over 10 palladium on carbon 4.6 g for 112 hours. The catalyst was filtered off and the solution washed with ether 3 x 150 ml .The aqueous was freeze dried to yield 2.5 g, 88 . vmax KBr 3300 br , 1765 br , 1700, 1605, 1505, 1370, 1200 br , 1105, 1010 and 900 cm,l, 6 D2O 0.84, 1.13, 1.27, 1.38 6H, 4 x s, 2 x 2CH3 , 2.28 6H, s, 2 xCH3CO , 3.27, 3.48 3H, 2 x s, OCH3 , 4.10, 4.17 1H, 2 x s, 3H , 5.18, 5.27 1H, 2 x s, CHCON , 5.45, 5.49 1H, 2 x s, 5H , 7.27 7.65 3H, m, Ar .iii Sodium 6,13 D,L 2 3 2 4 aminosulphonylphenyl amino 4 hydroxypyrimidin 5 yl ureido 2 3,4 diacetoxyphenyl acetamido 6,a methoxy penicillanate Prepared by the method described in example 1 except that 6, D,L 2 amino 3,4 diacetoxyphenyl acetamido 6, alpha methoxypenicillanate 0.98g, 2 mmol was used. Chromatography on silica gel eluting with ethyl acetate ethanol water 5 2 1 gave 0.16 g, 19.7 . vmax KBr 3350 br , 1765, 1660, 1600, 1535 and 1210cm 1, 6 CD3 2SO CD3OD 1.06, 1.33, 1.45 6H, 3 x s, 2 x 2CK3 , 2.23 6H, s, 2 x CH3CO , 3.17, 3.43 3H, 2 x s, OCH3 , 4.01, 4.10 1H, 2 x s , 3H , 5.42, 5.53, 5.61 2H, 3 x s, CHCON, 5H , 6.90 7.95 7H, m, 2 xAr , 8.28 1H, s, pyrimidin 6H . Biological data Antibacterial activities of a number of compounds described MIC ug ml .EMI41.1 tb SEP COMPOUND SEP OF SEP EXAMPLE SEP NO. tb SEP ORGANISM SEP 4 SEP 5 SEP 6 SEP SEP 7 SEP 8 SEP 9 SEP tb E. SEP Coli SEP JT SEP 425 SEP 1.0 SEP 2.5 SEP 8.0 SEP 1.0 SEP 16 SEP 1.0 tb Ps. SEP Aeruginosa SEP 10.0 SEP 50 SEP 32 SEP 16 SEP 128 SEP 1.0 tb 10662 tb Klebsiella SEP 0.2 SEP 1.0 SEP 0.12 SEP 0.25 SEP 8.0 SEP 0.06 tb Aerogenes SEP A tb P. SEP Mirabilis SEP 1.0 SEP 2.5 SEP 2.0 SEP 1.0 SEP 8.0 SEP 2.0 tb C977 tb Staph SEP Aureus SEP 10 SEP 25 SEP 16 SEP 16 SEP 64 SEP 128 tb Oxford tb